Skip to main content
Philip Hoffman, MD, Oncology, Chicago, IL

Philip C Hoffman MD

Breast Cancer, Hematologic Oncology, Thoracic Cancer


Professor of Medicine, University of Chicago Medicine

Join to View Full Profile
  • 5841 S Maryland AveChicago, IL 60637

  • Phone+1 888-824-0200

  • Fax+1 773-702-0963

Dr. Hoffman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Chicago
    University of ChicagoFellowship, Hematology and Medical Oncology, 1977 - 1980
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Internal Medicine, 1973 - 1975
  • Sidney Kimmel Medical College at Thomas Jefferson University
    Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1972

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 1977 - 2026
  • FL State Medical License
    FL State Medical License 2016 - 2021
  • PA State Medical License
    PA State Medical License 1973 - 2006
  • GA State Medical License
    GA State Medical License 1975 - 1987
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Hematology
    American Board of Internal Medicine Hematology
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2009-2014
  • Chicago Magazine: Top Doctors Castle Connolly, 2006, 2008, 2010, 2012, 2014
  • America's Top Doctors for Cancer Castle Connolly, 2005-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • 'Started Getting a Little Squirrely': What We Heard This Week
    'Started Getting a Little Squirrely': What We Heard This WeekFebruary 28th, 2020
  • First-Line Cyramza in NSCLC Gets Split Decision from FDA Panel
    First-Line Cyramza in NSCLC Gets Split Decision from FDA PanelFebruary 27th, 2020
  • FDA Panel: Thumbs down for Prostate Cancer Focal Therapy
    FDA Panel: Thumbs down for Prostate Cancer Focal TherapyFebruary 26th, 2020
  • Join now to see all

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: